✦ LIBER ✦

66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

✍ Scribed by M.S. Sulkowski; M. Bourliere; J.-P. Bronowicki; A. Streinu-Cercel; L. Preotescu; T. Asselah; J.-M. Pawlotsky; S. Shafran; S. Pol; F.A. Caruntu; S. Mauss; D. Larrey; C. Häfner; Y. Datsenko; J.O. Stern; R. Kubiak; W. Böcher; G. Steinmann

Book ID: 117379212
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 41 KB
Volume: 54
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(11)60068-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONS

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

✍ M.S. Sulkowski; E. Ceasu; T. Asselah; F.A. Caruntu; J. Lalezari; P. Ferenci; A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

✍ Sulkowski, M.; Bourliere, M.; Bronowicki, J.-P.; Streinu-Cercel, A.; Preotescu, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB

1366 HIGH SUSTAINED VIROLOGIC RESPONSE (

1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN

✍ Flamm, S.; Lawitz, E.; Jacobson, I.; Rubin, R.; Bourliere, M.; Hezode, C.; Vierl 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

505 The influence of cumulative exposure

505 The influence of cumulative exposure to combination peginterferon alfa-2A (40 KD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C

✍ K.R. Reddy; M.W. Fried; M.L. Shiffman; S.J. Hadziyannis; H. Sette; T.R. Morgan; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 49 KB

290 EARLY VIROLOGICAL RESPONSE PROFILES

290 EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR

✍ F. Poordad; J.G. McHutchison; M.L. Shiffman; T. Berg; A.J. Muir; M.P. Manns; A.M 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Mutation frequency of NS5A in patients v

Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy

✍ A. C. W. Jenke; S. Moser; V. Orth; M. Zilbauer; P. Gerner; S. Wirth 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB